Dr. Mark David Tricklebank, BSc MSc PhD DSc FBphS, earned his PhD from the University of Manchester, and after completing postdoctoral training at the Institute of Neurology, he joined the pharmaceutical company Merrell Dow in Strasbourg, where he was instrumental in the identification of the functional relevance of the newly identified 5-HT1A recognition site. He then moved to Merck at Terlings Park, where he worked with Susan Iversen to identify the behavioral effects of the NMDA receptor antagonist MK-801 and showed them to be identical to those of phencyclidine and ketamine. After then serving as head of the Mental Health Unit at Sandoz Pharma in Basel, he was appointed director of In Vivo Pharmacology at the Lilly Research Centre, Windlesham, where he conceived and founded the Lilly Centre for Cognitive Neuroscience, one of the first industrial-academic partnerships in the United Kingdom. After a varied career of several decades in the pharmaceutical industry, he now serves as a Wellcome Trust Fellow in the Institute of Psychiatry, Psychology and Neuroscience at King's College London, and has published more than 160 papers.